



## **ICC INTERNATIONAL CANNABIS CORP. ANNOUNCES COMMENCEMENT OF FIRST CBD FLOWER PRODUCTION FOR MEDICINAL PURPOSES**

### *Highlights*

- *ICC announces completion of 21,528 sq. ft. medicinal cannabis greenhouse for CBD flower production for medicinal purposes.*
- *The Company started germination of 4,000 seeds to harvest approximately 150 kilograms of CBD dried flower by October, 2017.*
- *ICC to build South America’s first extraction laboratory in Uruguay’s “science free trade zone” by April, 2018.*

**VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 31, 2017)** – ICC International Cannabis Corporation (“**ICC**” or the “**Company**”) (TSXV : ICC) is pleased to announce that, as part of its strategic plan to become the world’s largest and lowest cost producer of cannabidiol (“**CBD**”), the Company has completed the construction of a 21,528 sq. ft. greenhouse to increase CBD production for medicinal purposes.

The Company is also pleased to announce it has commenced the germination of 4,000 seeds to harvest approximately 150 kilograms of CBD dried flowers in October, 2017. In order to process its CBD oil and extracts, the Company’s first laboratory will be built in Uruguay’s “science free trade zone” by April, 2018.

“We are very excited that our CBD dry flower production has started. In addition, our new greenhouse and laboratory will allow us to keep improving our growing techniques with a view to optimizing future production,” commented Guillermo Delmonte, Chief Executive Officer of ICC, “The objective of ICC is to process its hemp crops into high quality CBD extracts, which are in high demand in the API (active pharmaceutical ingredient) market. We see a significant opportunity in the international CBD extracts market and ICC is positioning itself to become of the largest international providers of APIs.”

### **Medicinal Cannabis Greenhouse**

As part of the Company’s plan to become the world’s largest and lowest cost producer of CBD, the 21,528 sq. ft. greenhouse will allow ICC to test different cultivars’ behaviour throughout the

entire year and increase the production cycle of medicinal cannabis.

Working at its full capacity, this medicinal cannabis greenhouse will allow the Company to work with 4,000 plants per cycle, having at least three cycles per year resulting in a minimum of 12,000 plants per year for medicinal purposes. The first 4,000 plants are already being grown and the Company expects to harvest approximately 150 kilograms of dried flower by October, 2017.

The Company's CBD dry flower production will be developed in superior growing conditions to those of its Canadian peers and will be comprised of a 100% organic crop. In addition, ICC is committed to complying with GAP (Good Agricultural Practices) requirements in order to obtain this certification.

### **Extraction Laboratory**

ICC will set up the first cannabinoid extraction laboratory in South America using the Supercritical Fluid CO<sup>2</sup> extraction technique with state-of-the-art equipment from Europe. The Company will commence building the laboratory in Uruguay's "Science Free Trade Zone". The extraction laboratory will be situated in an area over 16,146 sq. ft. with construction set for completion in April, 2018.

The Company's cannabinoid extraction products will be processed under the highest quality standards. The Company is committed to complying with GMP (Good Manufacturing Practices) requirements.

### **ABOUT ICC INTERNATIONAL CANNABIS CORPORATION**

The Company has operations in Uruguay, and is focused on the licensed production, development and sale of recreational cannabis, cannabinoid extracts and other derivatives used for medicinal purposes and industrial hemp. For more information, please see the Company's filings on [www.sedar.com](http://www.sedar.com) and [www.intcannabiscorp.com](http://www.intcannabiscorp.com).

***Neither the TSX Venture Exchange ("TSXV") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.***

*Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the Company's ability to obtain any requisite regulatory approvals. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company's filings with Canadian securities regulators, which filings are available at [www.sedar.com](http://www.sedar.com).*

For more information, please contact:

ICC International Cannabis Corporation  
Guillermo Delmonte, Chief Executive Officer and Director  
t: 598-2900-0000  
e: [ir@intcannabiscorp.com](mailto:ir@intcannabiscorp.com)